Comparative Pharmacology
Head-to-head clinical analysis: TRINTELLIX versus ZULRESSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRINTELLIX versus ZULRESSO.
TRINTELLIX vs ZULRESSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trintellix (vortioxetine) is a serotonin modulator and reuptake inhibitor. Its exact mechanism is not fully understood, but it is thought to work by inhibiting the reuptake of serotonin (5-HT) and by modulating several serotonin receptors, including 5-HT1A agonism, 5-HT1B partial agonism, 5-HT3 and 5-HT7 antagonism.
Allopregnanolone is a positive allosteric modulator of GABAA receptors, enhancing phasic and tonic inhibition via binding to delta-subunit-containing receptors.
10 mg orally once daily initially, then increase to 20 mg orally once daily based on tolerability; maximum 20 mg/day.
Initial: 30 mcg/min IV infusion for 0-4 hours, then increase by 30 mcg/min every 4 hours if tolerated, maximum 120 mcg/min; typical duration up to 60 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 66 hours (range 58-78 hours) for vortioxetine. This supports once-daily dosing; steady-state is reached within 2-3 weeks.
Terminal elimination half-life is approximately 18 hours (range 15-23 hours) following intravenous administration; clinically, this supports once-daily dosing.
Primarily hepatic metabolism via CYP3A4 and CYP2C19, with approximately 26% of the dose recovered in urine (mostly as metabolites) and 60% in feces (mostly as metabolites). Less than 1% excreted as unchanged drug in urine.
Primarily via renal excretion as unchanged drug (approximately 90% of dose) and minor fecal elimination (approximately 5%); no active metabolites identified.
Category C
Category C
Antidepressant
Antidepressant